NICE recently published guidance on 10 artificial intelligence technologies designed to detect or characterise colorectal polyps. While 6 tools have been conditionally recommended for NHS use, the economic and clinical real-world impact remains uncertain. We unpack what this means for gastroenterologists, the 4-year evidence generation plan, and why finding more polyps does not automatically equal preventing more cancer.
Key points
NICE recommends 6 AI technologies for use in the NHS during a 4 years evidence generation period for people without diagnosed IBD or Lynch syndrome.
Clinical evidence shows AI improves the adenoma detection rate overall, but mostly for smaller polyps (less than 5 mm) rather than advanced adenomas.
The cost-effectiveness of these tools is highly uncertain, hovering at a 50% probability at NICE's willingness-to-pay range of £20,000 to £30,000.
More research is required for AI tools that characterise polyps and for using AI in patients with inflammatory bowel disease or Lynch syndrome.
Increased detection of benign polyps could lead to uncaptured downstream costs, including more histology testing and unnecessary surveillance colonoscopies.
This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show
This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.
Podden och tillhörande omslagsbild på den här sidan tillhör
Mike Rawson. Innehållet i podden är skapat av Mike Rawson och inte av,
eller tillsammans med, Poddtoppen.
